Innoviva Inc. (INVA) 11.35 $INVA
Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:40AM CDT
Glaxo (GSK) and Innoviva (INVA) will file an NDA in the U.S. for the closed triple combination therapy (FF/UMEC/VI) for the treatment of COPD by the end of 2016.
INVA: 11.35 (-0.09), TBPH: 23.29 (-0.54), GSK: 42.70 (-0.15), BMY: 73.91 (-0.38)
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
PR Newswire - Thu Jun 02, 10:00AM CDT
GlaxoSmithKline plc (LSE: GSK) and Innoviva, Inc. (Nasdaq: INVA) today announced that, following discussions with the US Food and Drug Administration (FDA), GSK has brought forward the plan to file a New Drug Application (NDA) in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled corticosteroid, longacting muscarinic antagonist, long-acting beta agonist) for patients with chronic obstructive pulmonary disease (COPD). The US regulatory submission is now anticipated by the end of 2016, rather than the first half of 2018, as previously expected.
INVA: 11.35 (-0.09), GSK: 42.70 (-0.15)
Regulatory Update on US Filing Plans for Closed Triple Combination Therapy FF/UMEC/VI in Patients With COPD
Marketwired - Thu Jun 02, 1:00AM CDT
Acceleration of Filing of US New Drug Application Now Expected by End of 2016
INVA: 11.35 (-0.09), GSK: 42.70 (-0.15)
Innoviva to Present at Jefferies 2016 Healthcare Conference on June 10
Marketwired - Wed Jun 01, 3:05PM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 1, 2016) - Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Friday, June 10, at 11:00 a.m. ET at the Grand Hyatt Hotel, New York.
INVA: 11.35 (-0.09)
Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta
Zacks Equity Research - Zacks Investment Research - Wed May 25, 10:21AM CDT
GlaxoSmithKline (GSK) and partner Innoviva reported positive headline data from a phase IIIb chronic obstructive pulmonary disease study on Relvar Ellipta.
INVA: 11.35 (-0.09), ANIP: 55.52 (-0.24), GSK: 42.70 (-0.15), BMY: 73.91 (-0.38)
Salford Lung Study Results Show COPD Patients Treated With Relvar(R) Ellipta(R) Achieve Superior Reduction in Exacerbations Compared to 'Usual Care'
Marketwire Canada - Tue May 24, 5:01AM CDT
Pioneering GSK Study Provides Important New Data on the Effectiveness of Relvar Ellipta (FF/VI) When Used in Everyday Clinical Practice
INVA: 11.35 (-0.09), GSK: 42.70 (-0.15)
Glaxo/Innoviva Unveil SUMMIT Study Data on Breo Ellipta
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:14AM CDT
Glaxo (GSK) and Innoviva (INVA) have announced results of two pre-specified analyses from the SUMMIT study on Breo Ellipta.
INVA: 11.35 (-0.09), ANIP: 55.52 (-0.24), GSK: 42.70 (-0.15), BMY: 73.91 (-0.38)
GSK Presents Efficacy Data for Anoro(R) Ellipta(R) in COPD Patients Who Remained Symptomatic on Tiotropium
Marketwire Canada - Wed May 18, 11:22AM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - May 18, 2016) - GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the efficacy and safety of Anoro® Ellipta® (umeclidinium/vilanterol, 'UMEC/VI'
in patients with moderate chronic obstructive pulmonary disease (COPD) who continued to have symptoms while on tiotropium monotherapy.
INVA: 11.35 (-0.09), GSK: 42.70 (-0.15)
GSK Present New Data From Breo(R) Ellipta(R) SUMMIT Study in Patients With COPD at ATS Conference
Marketwire Canada - Wed May 18, 11:22AM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - May 18, 2016) - GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that GlaxoSmithKline plc (GSK) presented new data at the American Thoracic Society (ATS) Conference from two pre-specified analyses from the Study to Understand Mortality and MorbidITy (SUMMIT) trial. One demonstrated that patients with Chronic Obstructive Pulmonary Disease (COPD) and moderate airflow limitation receiving Breo® Ellipta® (fluticasone furoate/vilanterol or FF/VI 100/25mcg) achieved improvements in exacerbations compared with placebo. The second analysis demonstrated these patients reported similar rates of pneumonia when taking FF/VI 100/25mcg compared with placebo.
INVA: 11.35 (-0.09), GSK: 42.70 (-0.15)
Innoviva to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11
Marketwired - Tue May 03, 5:57PM CDT
Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11 at 8:40 a.m. PT, at the Wynn Las Vegas in Las Vegas.
INVA: 11.35 (-0.09)
Innoviva meets 1Q profit forecasts
Automated Insights - Thu Apr 28, 4:25PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Innoviva Inc. (INVA) on Thursday reported first-quarter net income of $4.4 million, after reporting a loss in the same period a year earlier.
INVA: 11.35 (-0.09)
Innoviva Reports First Quarter 2016 Financial Results
Marketwired - Thu Apr 28, 3:05PM CDT
Innoviva, Inc. (NASDAQ: INVA)
INVA: 11.35 (-0.09)
Alexion (ALXN) Q1 Earnings: What's in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 5:53PM CDT
Alexion (ALXN) will report first-quarter 2016 earnings on Apr 28 before market opens.
BMRN: 85.50 (-4.02), INVA: 11.35 (-0.09), ALXN: 138.13 (-16.86), SNY: 41.30 (+0.14)
What's in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
Ananya Ghosh - Zacks Investment Research - Tue Apr 26, 3:13PM CDT
ImmunoGen (IMGN) will report third-quarter fiscal 2016 results on Apr 29 before the market opens.
INVA: 11.35 (-0.09), IMGN: 5.45 (-0.20), SNY: 41.30 (+0.14)
Biotech Stock Gilead (GILD) Likely to Beat in Q1 Earnings
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 10:37AM CDT
Gilead Sciences (GILD), which is set to report first-quarter 2016 results on Apr 28, delivered a positive earnings surprise of 12.37% last quarter.
INVA: 11.35 (-0.09), GILD: 87.50 (-0.10), AMGN: 158.89 (-1.30), ABBV: 63.10 (+0.28)
Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:40AM CDT
Glaxo (GSK) and Innoviva (INVA) will file an NDA in the U.S. for the closed triple combination therapy (FF/UMEC/VI) for the treatment of COPD by the end of 2016.
INVA: 11.35 (-0.09), TBPH: 23.29 (-0.54), GSK: 42.70 (-0.15), BMY: 73.91 (-0.38)
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
PR Newswire - Thu Jun 02, 10:00AM CDT
GlaxoSmithKline plc (LSE: GSK) and Innoviva, Inc. (Nasdaq: INVA) today announced that, following discussions with the US Food and Drug Administration (FDA), GSK has brought forward the plan to file a New Drug Application (NDA) in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled corticosteroid, longacting muscarinic antagonist, long-acting beta agonist) for patients with chronic obstructive pulmonary disease (COPD). The US regulatory submission is now anticipated by the end of 2016, rather than the first half of 2018, as previously expected.
INVA: 11.35 (-0.09), GSK: 42.70 (-0.15)
Regulatory Update on US Filing Plans for Closed Triple Combination Therapy FF/UMEC/VI in Patients With COPD
Marketwired - Thu Jun 02, 1:00AM CDT
Acceleration of Filing of US New Drug Application Now Expected by End of 2016
INVA: 11.35 (-0.09), GSK: 42.70 (-0.15)
Innoviva to Present at Jefferies 2016 Healthcare Conference on June 10
Marketwired - Wed Jun 01, 3:05PM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 1, 2016) - Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Friday, June 10, at 11:00 a.m. ET at the Grand Hyatt Hotel, New York.
INVA: 11.35 (-0.09)
Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta
Zacks Equity Research - Zacks Investment Research - Wed May 25, 10:21AM CDT
GlaxoSmithKline (GSK) and partner Innoviva reported positive headline data from a phase IIIb chronic obstructive pulmonary disease study on Relvar Ellipta.
INVA: 11.35 (-0.09), ANIP: 55.52 (-0.24), GSK: 42.70 (-0.15), BMY: 73.91 (-0.38)
Salford Lung Study Results Show COPD Patients Treated With Relvar(R) Ellipta(R) Achieve Superior Reduction in Exacerbations Compared to 'Usual Care'
Marketwire Canada - Tue May 24, 5:01AM CDT
Pioneering GSK Study Provides Important New Data on the Effectiveness of Relvar Ellipta (FF/VI) When Used in Everyday Clinical Practice
INVA: 11.35 (-0.09), GSK: 42.70 (-0.15)
Glaxo/Innoviva Unveil SUMMIT Study Data on Breo Ellipta
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:14AM CDT
Glaxo (GSK) and Innoviva (INVA) have announced results of two pre-specified analyses from the SUMMIT study on Breo Ellipta.
INVA: 11.35 (-0.09), ANIP: 55.52 (-0.24), GSK: 42.70 (-0.15), BMY: 73.91 (-0.38)
GSK Presents Efficacy Data for Anoro(R) Ellipta(R) in COPD Patients Who Remained Symptomatic on Tiotropium
Marketwire Canada - Wed May 18, 11:22AM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - May 18, 2016) - GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the efficacy and safety of Anoro® Ellipta® (umeclidinium/vilanterol, 'UMEC/VI'
in patients with moderate chronic obstructive pulmonary disease (COPD) who continued to have symptoms while on tiotropium monotherapy. INVA: 11.35 (-0.09), GSK: 42.70 (-0.15)
GSK Present New Data From Breo(R) Ellipta(R) SUMMIT Study in Patients With COPD at ATS Conference
Marketwire Canada - Wed May 18, 11:22AM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - May 18, 2016) - GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that GlaxoSmithKline plc (GSK) presented new data at the American Thoracic Society (ATS) Conference from two pre-specified analyses from the Study to Understand Mortality and MorbidITy (SUMMIT) trial. One demonstrated that patients with Chronic Obstructive Pulmonary Disease (COPD) and moderate airflow limitation receiving Breo® Ellipta® (fluticasone furoate/vilanterol or FF/VI 100/25mcg) achieved improvements in exacerbations compared with placebo. The second analysis demonstrated these patients reported similar rates of pneumonia when taking FF/VI 100/25mcg compared with placebo.
INVA: 11.35 (-0.09), GSK: 42.70 (-0.15)
Innoviva to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11
Marketwired - Tue May 03, 5:57PM CDT
Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11 at 8:40 a.m. PT, at the Wynn Las Vegas in Las Vegas.
INVA: 11.35 (-0.09)
Innoviva meets 1Q profit forecasts
Automated Insights - Thu Apr 28, 4:25PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Innoviva Inc. (INVA) on Thursday reported first-quarter net income of $4.4 million, after reporting a loss in the same period a year earlier.
INVA: 11.35 (-0.09)
Innoviva Reports First Quarter 2016 Financial Results
Marketwired - Thu Apr 28, 3:05PM CDT
Innoviva, Inc. (NASDAQ: INVA)
INVA: 11.35 (-0.09)
Alexion (ALXN) Q1 Earnings: What's in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 5:53PM CDT
Alexion (ALXN) will report first-quarter 2016 earnings on Apr 28 before market opens.
BMRN: 85.50 (-4.02), INVA: 11.35 (-0.09), ALXN: 138.13 (-16.86), SNY: 41.30 (+0.14)
What's in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
Ananya Ghosh - Zacks Investment Research - Tue Apr 26, 3:13PM CDT
ImmunoGen (IMGN) will report third-quarter fiscal 2016 results on Apr 29 before the market opens.
INVA: 11.35 (-0.09), IMGN: 5.45 (-0.20), SNY: 41.30 (+0.14)
Biotech Stock Gilead (GILD) Likely to Beat in Q1 Earnings
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 10:37AM CDT
Gilead Sciences (GILD), which is set to report first-quarter 2016 results on Apr 28, delivered a positive earnings surprise of 12.37% last quarter.
INVA: 11.35 (-0.09), GILD: 87.50 (-0.10), AMGN: 158.89 (-1.30), ABBV: 63.10 (+0.28)
